[1]XU L,ZOU C,ZHANG S,et al.Reshaping the systemic tumor immune environment(STIE) and tumor immune microenvironment(TIME) to enhance immunotherapy efficacy in solid tumors[J].J Hematol Oncol,2022,15(1):87.
[2]WEBER JS.Biomarkers for checkpoint inhibition[J].Am Soc Clin Oncol Educ Book,2017,37:205-209.
[3] ALVES A,DIAS M,CAMPAINHA S,et al.Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy[J].J Thorac Dis,2021,13(5):2716-2727.
[4] PONCIN A,ONESTI CE,JOSSE C,et al.Immunity and breast cancer:Focus on eosinophils[J].Biomedicines,2021,9(9):1087.
[5] MA Y,SHANG K,WU S,et al.The prognostic value of albumin-globulin ratio and eosinophil-neutrophil ratio in patients with advanced tumors undergoing treatment with PD-1/PD-L1 inhibitors[J].Nutr Cancer,2022,74(8):2815-2828.
[6]HWANG M,CANZONIERO JV,ROSNER S,et al.Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy[J].J Immunother Cancer,2022,10(6):e004688.
[7]AN HJ,CHON HJ,KIM C.Peripheral blood-based biomarkers for immune checkpoint inhibitors[J].Int J Mol Sci,2021,22(17):9414.
[8] LI F,DU X,LAN F,et al.Eosinophilic inflammation promotes CCL6-dependent metastatic tumor growth[J].Sci Adv,2021,7(22):eabb5943.
[9] TUCKER MD,BROWN LC,CHEN YW,et al.Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma[J].Biomark Res,2021,9(1):80.
[10] CEDERBERG RA,FRANKS SE,WADSWORTH BJ,et al.Eosinophils decrease pulmonary metastatic mammary tumor growth[J].Front Oncol,2022,12:841921.
[11] LIU Z,LIANG Y,TANG X,et al.Decrease in blood neutrophil-to-lymphocyte ratio indicates better survival after neoadjuvant chemotherapy in patients with advanced gastric cancer[J].Front Surg,2021,8:745748.
[12] DAI W,QIU X,LU C,et al.AGIG chemo-immunotherapy in patients with advanced pancreatic cancer:A single-arm,single-center,phase 2 study[J].Front Oncol,2021,11:693386.
[13]BAI X,DAI J,LI C,et al.Risk models for advanced melanoma patients under anti-PD-1 monotherapy-Ad hoc analyses of pooled data from two clinical trials[J].Front Oncol,2021,11:639085.
[14]DU J,LU C,MAO L,et al.PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC:A biomolecular exploratory,phase II trial[J].Cell Rep Med,2023:100972.
[15] CHENNAMADHAVUNI A,ABUSHAHIN L,JIN N,et al.Risk factors and biomarkers for immune-related adverse events:A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors[J].Front Immunol,2022,13:779691.
[16] HWANG M,CANZONIERO JV,ROSNER S,et al.Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy[J].Journal for ImmunoTherapy of Cancer,2022,10(6):e004688.
[17]MA Y,MA X,WANG J,et al.Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors:a retrospective analysis[J].World J Surg Oncol,2022,20(1):242.